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One sees only what one knows.
Johann Wolfgang von Goethe
Thus we ignore what we don’t know.
In oncology, it is traditionally assumed 
that men and women are equal. As a result, 
sex differences in treatment effects and 
the biology of non- sex- related cancers have 
largely been ignored in the last decades. 
However, the observation of increased 
chemotherapy toxicity in women is not new. 
Although overall insufficiently studied, avail-
able data from different types of tumours1–4 
clearly demonstrate that women are more 
susceptible to toxicity from various types of 
chemotherapy.
WHY DO DIFFERENCES IN TOXICITY EXIST?
Theoretically, sex differences in drug effects 
can be broken down into two categories:
1. Differences in pharmacokinetics: sex dif-
ferences in pharmacokinetics have been 
reviewed elsewhere5 and affect the dif-
ferent types of pharmacokinetic parame-
ters, such as bioavailability, distribution, 
metabolism and excretion.6 Examples for 
chemotherapeutic drugs with significant 
sex differences in pharmacokinetics are 
5- fluouracil7 and paclitaxel.8 However, 
the impact of the patients’ sex is most of-
ten not analysed, and/or subgroup anal-
yses according to sex are not reported 
in pharmacokinetic studies and clinical 
trials. According to a recent literature 
survey of population pharmacokinetic 
studies of anticancer drugs,9 among 256 
studies identified, only 80 reported sex as 
a tested covariate.
2. Differences in pharmacodynamics: in ad-
dition to differences in drug metabolism, 
the sensitivity of both normal tissues and 
tumours in men and women may be dif-
ferent. Furthermore, the dose–response 
and dose- toxicity relationships may not 
necessarily be the same in both sexes.
SEX DIFFERENCES IN TREATMENT EFFECTS GO 
BEYOND DIFFERENCES IN TOXICITY
While differences in incidence and mortality 
of different types of cancers have initially 
been attributed to differences in exposure 
to risk factors, evidence from large epide-
miologic studies clearly indicates significant 
sex differences in susceptibility and survival 
of non- sex- related cancers, which cannot be 
explained by differences in behaviour. Cloc-
chiatti and colleagues introduced the term 
‘sexual dimorphism in cancer’ to describe 
this observation.10 In addition, sex- biassed 
gene- expression signatures have been 
described for multiple solid tumours.11 Sex 
differences in host factors, especially the 
immune responses, differentially affect the 
susceptibility to many diseases, especially 
autoimmune diseases, but as well infectious 
diseases and non- reproductive cancers.12
WHY DO SEX DIFFERENCES MATTER IN 
ONCOLOGY?
Understanding sex differences in treatment 
effects is key for three major reasons:
First: The balance between efficacy and 
toxicity may be improved by the development 
of rationally designed, sex-specific dose 
modifications
The SEXIE- R- CHOP-14 trial (Optimization 
of rituximab for the treatment of DLBCL: 
increasing the dose for elderly male patients)13 
prospectively investigated different doses of 
rituximab in men and women with diffuse 
large B- cell lymphoma and demonstrated 
an improved progression- free survival by 
32.5% (p=0.039), with a trend for a (30%) 
better overall survival in the experimental 
arm. It demonstrates the feasibility and is 
an example for the potential of rationally 
designed, sex- specific dose modifications 
to improve patient outcomes in oncology. 
Further studies with other classes of drugs 
with significant sex differences in pharma-
cokinetics are required. The current process 
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of drug development in oncology does not identify poten-
tially different optimal doses for men and women. Cardi-
ologists recently discovered that optimal doses of drugs to 
treat heart failure are not the same14 in women as in men. 
We should learn from them.
Second: Due to potential differences in tumour biology, the 
magnitude of the treatment benefit may be different in men 
and women
One example of a recent study with significant differ-
ences in treatment efficacy between men and women is 
the BILCAP (Capecitabine compared with observation 
in resected biliary tract cancer) study, in which adjuvant 
treatment with capecitabine after curatively resected 
biliary cancer was compared with observation alone.15 
The subgroup analysis of this trial demonstrated a HR of 
0.93 (0.64–1.35) in women and 0.7 (0.50–0.99) in men. 
Certainly, the result of the subgroup analysis in women is 
limited by its small sample size and may be false. This trial 
was neither designed nor powered to detect a treatment 
benefit in women. A subgroup analysis is not a sufficient 
argument to withhold a potentially effective treatment for 
women with biliary cancer. However, these results should 
raise doubts about the efficacy of capecitabine as adju-
vant treatment in women with biliary cancer as they may 
as well reflect true biological differences in sensitivity of 
this type of cancer to capecitabine. Further research and 
trials specifically addressing this question are necessary to 
confirm or infirm the efficacy of adjuvant capecitabine 
for biliary cancer in women. Since we understand the 
concept of a sexual dimorphism in cancer,10 we can no 
longer conclude from the observation of a certain treat-
ment benefit in men that this benefit will be the same in 
women.
Third: Understanding of the biological basis of sex differences 
in tumour biology might allow for the development of sex-
specific drugs with greater efficacy
The recent ESMO workshop concluded that ‘especially 
in diseases with significant differences in epidemiology or 
outcomes, men and women with non- sex- related cancers 
should be considered as biologically distinct groups of 
patients, for whom specific treatment approaches merit 
consideration’.9 Another example for a disease with a 
significant difference in tumour biology between men 
and women is melanoma: a pooled analysis of 2734 
patients included in five randomised trials reported in 
201316 clearly described a significantly better survival (HR 
0.81, 95% CI 0.72 to 0.91, p<0.001) in stage III and stage 
IV (HR 0.82, 95% CI 0.72 to 0.93, p<0.001). The authors 
conclude that ‘a biologic sex trait seems to profoundly 
influence melanoma progression and survival’. Further 
research is necessary to identify and understand such 
biological differences.
Finally, when thinking about the individualisation 
of systemic treatments in oncology, we have to keep in 
mind that the patients’ sex is only one of different host 
factors, which deserves consideration: a patients’ body 
composition is an example of another one. Body surface 
area (BSA)- based dosing of chemotherapy has been intro-
duced in the 1950s and remained the default approach 
since then. Its inaccuracy has already been discussed 
nearly 25 years ago,17 18 and more recently by Bins et 
al,19 where paclitaxel is taken as an example to illustrate 
both the lack of correlation between clearance and BSA, 
and the impact of the patients’ sex. BSA- based dosing of 
chemotherapy ignores both the sex differences in fat- free 
body mass and the large individual variations of body 
composition, which can easily and precisely be assessed by 
CT scanning.9 In an editorial published in 1998,20 Ratain 
asked if BSA- based dosing of chemotherapy is ‘science, 
myth or habit?’ and concluded that myth and habit have 
gotten in the way of science. Alternatives to chemotherapy 
dosing according to BSA, such as toxicity- based dosing, 
genotype- based dosing or therapeutic drug monitoring 
(TDM) have been developed. However, the complexities 
of TDM make its universal use impractical,17 genotype- 
based dosing is possible only for a limited number of 
drugs and in a limited number of settings, but informa-
tion about the patients’ host factors, such as sex, age and 
body composition, as well as treatment- related toxicity, is 
available wherever oncology is practiced.
We are now in 2020 and should put greater efforts in 
the investigation of alternatives to BSA- based dosing of 
chemotherapy. Rationally designed concepts for chemo-
therapy dosing, developed on the basis of the under-
standing of a drugs’ pharmacokinetics, which integrate 
information about the relation between host factors, such 
as sex, age and body composition and drug clearance, as 
well as genotypes wherever possible, need further devel-
opment. Furthermore, dose adjustment according to 
toxicity should not be limited to reductions in presence 
of toxicity. The potential of uptitration of chemotherapy 
doses in absence of toxicity in eligible patients to increase 
treatment efficacy deserves further investigation. Ideally, 
composite models, which take these different parame-
ters according to their specific relevance for a given drug 
into account, should be developed. The clinical benefit 
of such new concepts in terms of reduction of toxicity 
and improvement of efficacy needs confirmation in 
randomised clinical trials.
Finally, body composition matters not only for chemo-
therapy dosing, but might also affect the results of immu-
notherapy.21 By individualising cancer treatments on the 
basis of tumour characteristics we made significant prog-
ress. We have understood the importance of the microen-
vironment and are exploring the role of the microbiome. 
We should now continue and explore the impact of host 
factors, such as sex and body composition, as well as their 
interactions with tumour biology and treatment effects, 
to further individualise the administration of anticancer 
treatments.
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